WBR0401

Author	[[PageAuthor::Gonzalo A. Romero, M.D. [1]]]
Exam Type	ExamType::USMLE Step 1
Main Category	MainCategory::Pharmacology
Sub Category	SubCategory::Cardiology, SubCategory::Vascular
Prompt	[[Prompt::A novel drug is being developed by a group of basic science researchers. The drug is being studied under animal models using specific cardiovascular receptors. The research team measures the drug’s effects on the ventricular membrane potential. They determine that the drug increases the action potential duration (APD) by increasing the effective refractory period (ERP). Detail molecular studies determine that the drug works by blocking the potassium channels. Which of the following drugs is an analogue of the novel drug?]]
Answer A	AnswerA::Sotalol
Answer A Explanation	[[AnswerAExp::Correct.]]
Answer B	AnswerB::Metoprolol
Answer B Explanation	[[AnswerBExp::Incorrect.]]
Answer C	AnswerC::Lidocaine
Answer C Explanation	[[AnswerCExp::Incorrect.]]
Answer D	AnswerD::Verapamil
Answer D Explanation	[[AnswerDExp::Incorrect.]]
Answer E	AnswerE::Mexiletine
Answer E Explanation	[[AnswerEExp::Incorrect.]]
Right Answer	RightAnswer::A
Explanation	[[Explanation::The anti-arrhythmic classification is commonly tested on USMLE. The classification is as follows File:Anti-arrhytmic.png Educational Objective: Sotalol is a potasium channel blocker (class III) anti-arrhythmic. Educational Objective: References: ]]
Approved	Approved::No
Keyword
Linked Question	Linked::
Order in Linked Questions	LinkedOrder::